Navigation Links
KaloBios' KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Date:9/18/2013

.
  • KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi and is being developed for the prevention and treatment of Pa infection. KaloBios has retained rights for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios received Orphan Drug Status from the European Commission regarding its applications for KB001-A for the treatment of Pa lung infection in CF. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's clinical development of KB001-
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    2. KaloBios Pharmaceuticals Completes Initial Public Offering
    3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
    4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
    6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
    7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
    8. KaloBios to Present at Needham Healthcare Conference
    9. KaloBios Reports First Quarter 2013 Financial Results
    10. KaloBios to Present at Stifel Healthcare Conference 2013
    11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... , July 29, 2015   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... second quarter 2015 financial results will be released on ... host a conference call and live webcast at 1:30 ...
    (Date:7/28/2015)... July 28, 2015 Amgen (NASDAQ: AMGN ... a $0.79 per share dividend for the third quarter ... 8, 2015, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
    (Date:7/28/2015)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) announced ... results after the market closes on Tuesday, August 4, ... be held on Tuesday, August 4, 2015, at 4:30 ... To participate in the call, please dial 877-303-1298 (for ... of the teleconference will be available for one week ...
    Breaking Medicine Technology:BioLife Solutions to Report Second Quarter 2015 Financial Results and Provide Business Update on August 6, 2015 2Amgen Announces 2015 Third Quarter Dividend 2Amgen Announces 2015 Third Quarter Dividend 3Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2
    ... N.J., Feb. 27, 2012    Octapharma USA has submitted ... the U.S. Food and Drug Administration (FDA) with ... fourth quarter of 2012. The FDA will evaluate ... preoperative or bleeding patients who require replacement of multiple plasma ...
    ... ST. LOUIS, Feb. 27, 2012 Stereotaxis, Inc. (NASDAQ: ... release financial results for the fourth quarter and full ... 2012 after the close of the U.S. financial markets.  ... at 4:30 p.m. Eastern Time that day to discuss ...
    Cached Medicine Technology:Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 2Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 3Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012 2Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012 3
    (Date:7/29/2015)... ... July 29, 2015 , ... July is National UV Awareness Month, and in honor of ... tips on how to protect skin from the sun, as well as how to best ... is one of the most common skin conditions in America. Many people do not protect ...
    (Date:7/29/2015)... ... July 29, 2015 , ... It is unique for a health center ... model of care. One that is very hands on and resident oriented, and one ... Landing. “She’s bringing great passion and energy, as well as a strong commitment to ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to ... autism, Little City took a proactive stance and began planning the Children’s Village consisting ... provides valuable support to building the third home. , “We are very pleased to ...
    (Date:7/29/2015)... ... July 29, 2015 , ... ... the Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical ...
    (Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... " mybody ... a look at small, medium and large businesses making an impact in their industry. ... shared with viewers how these advanced probiotic skincare products are designed to strengthen the ...
    Breaking Medicine News(10 mins):Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2
    ... Devoted dog owners know,the dilemma -- my dog is old and ... I know when to let him go to the big dog ... Colorado fee-only financial planner, knows,the problem well. "A large number of ... vets when it,s time to say goodbye. In response,to the question: ...
    ... , News Facts , ... organization (CRO) based in Madrid,Spain, has deployed Oracle(R) Clinical applications to ... well as plans for continued,expansion in the global clinical trial market. ... manages approximately eight to 12 global clinical,trials annually and is involved ...
    ... of Toxic PVC Baby Products, Toys, & Other Products for Children ... CHURCH, Va., Nov. 24 A new guide released today ... consumers worried about toxic chemicals in toys, baby products, and the ... Poison Plastic -- the PVC-Free Guide for Your Family & Home ...
    ... Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain Management Products ... King Extends Tender Offer Through December 19, 2008 , ... 24 King Pharmaceuticals, Inc. (NYSE: KG ) and ... two companies have signed a definitive merger agreement under which King ...
    ... Gift for Your Loved One , , ... find the perfect gift for a loved one with vision loss, ... Guide that contains gift ideas for game lovers, craft enthusiasts, movie ... list are all fully accessible and help people with low vision ...
    ... JOLLA, Calif., Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC ... the development and commercialization of non-invasive,topically targeted medications, ... to the Company,s Board of Directors. , ... president of Swann, Inc., a consulting firm specializing ...
    Cached Medicine News:Health News:Author Pens Pet Guardian Self-Defense Manual 2Health News:Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth 2Health News:Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth 3Health News:New Consumer Health Guide -- 'Pass Up the Poison Plastic, The PVC-Free Guide for Your Family & Home' Released Just in Time for the Holiday Shopping Season 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Ultimate Holiday Guide for Friends and Family of People with Vision Loss from the American Foundation for the Blind 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3
    ... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
    ... detection of SYBR Green I or FAM ... of fluorophores in the second channel ... for a multitude of applications such as ... cycler offers precision thermal control and a ...
    Mx3000P instrument, notebook computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, H...
    Mx3000P instrument, notebook computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, H...
    Medicine Products: